Nuvectis Pharma (NVCT) Competitors

$10.94 +0.31 (+2.92%)

Closing price 04:00 PM Eastern

Extended Trading

$10.93 -0.01 (-0.09%)

As of 04:12 PM Eastern

NVCT vs. COLL, DBVT, EVO, ALVO, and XERS

Should you buy Nuvectis Pharma stock or one of its competitors? MarketBeat compares Nuvectis Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nuvectis Pharma include Collegium Pharmaceutical (COLL), DBV Technologies (DBVT), Evotec (EVO), Alvotech (ALVO), and Xeris Biopharma (XERS). These companies are all part of the "pharmaceutical products" industry.

How does Nuvectis Pharma compare to Collegium Pharmaceutical?

Collegium Pharmaceutical (NASDAQ:COLL) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Collegium Pharmaceutical currently has a consensus target price of $57.50, indicating a potential upside of 67.05%. Nuvectis Pharma has a consensus target price of $10.00, indicating a potential downside of 8.59%. Given Collegium Pharmaceutical's stronger consensus rating and higher probable upside, equities analysts plainly believe Collegium Pharmaceutical is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Collegium Pharmaceutical has a net margin of 9.41% compared to Nuvectis Pharma's net margin of 0.00%. Collegium Pharmaceutical's return on equity of 95.18% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	9.41%	95.18%	16.39%
Nuvectis Pharma	N/A	-161.00%	-98.88%

Collegium Pharmaceutical has higher revenue and earnings than Nuvectis Pharma. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$780.57M	1.43	$62.87M	$2.04	16.87
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A

Collegium Pharmaceutical has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.11, meaning that its share price is 111% less volatile than the broader market.

In the previous week, Collegium Pharmaceutical had 5 more articles in the media than Nuvectis Pharma. MarketBeat recorded 5 mentions for Collegium Pharmaceutical and 0 mentions for Nuvectis Pharma. Collegium Pharmaceutical's average media sentiment score of 0.02 beat Nuvectis Pharma's score of 0.00 indicating that Collegium Pharmaceutical is being referred to more favorably in the media.

Company	Overall Sentiment
Collegium Pharmaceutical	Neutral
Nuvectis Pharma	Neutral

96.8% of Nuvectis Pharma shares are held by institutional investors. 1.9% of Collegium Pharmaceutical shares are held by company insiders. Comparatively, 30.5% of Nuvectis Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Collegium Pharmaceutical beats Nuvectis Pharma on 13 of the 15 factors compared between the two stocks.

How does Nuvectis Pharma compare to DBV Technologies?

DBV Technologies (NASDAQ:DBVT) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.

DBV Technologies presently has a consensus price target of $40.25, suggesting a potential upside of 116.75%. Nuvectis Pharma has a consensus price target of $10.00, suggesting a potential downside of 8.59%. Given DBV Technologies' stronger consensus rating and higher possible upside, research analysts plainly believe DBV Technologies is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.67
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Nuvectis Pharma has lower revenue, but higher earnings than DBV Technologies. Nuvectis Pharma is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	194.95	-$146.95M	-$4.46	N/A
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A

DBV Technologies has a beta of -0.96, indicating that its stock price is 196% less volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.11, indicating that its stock price is 111% less volatile than the broader market.

Nuvectis Pharma has a net margin of 0.00% compared to DBV Technologies' net margin of -2,895.37%. DBV Technologies' return on equity of -129.88% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-2,895.37%	-129.88%	-88.84%
Nuvectis Pharma	N/A	-161.00%	-98.88%

In the previous week, DBV Technologies had 2 more articles in the media than Nuvectis Pharma. MarketBeat recorded 2 mentions for DBV Technologies and 0 mentions for Nuvectis Pharma. DBV Technologies' average media sentiment score of 0.00 equaled Nuvectis Pharma'saverage media sentiment score.

Company	Overall Sentiment
DBV Technologies	Neutral
Nuvectis Pharma	Neutral

71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are held by institutional investors. 1.1% of DBV Technologies shares are held by company insiders. Comparatively, 30.5% of Nuvectis Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

DBV Technologies beats Nuvectis Pharma on 9 of the 15 factors compared between the two stocks.

How does Nuvectis Pharma compare to Evotec?

Nuvectis Pharma (NASDAQ:NVCT) and Evotec (NASDAQ:EVO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

Nuvectis Pharma has a beta of -0.11, meaning that its share price is 111% less volatile than the broader market. Comparatively, Evotec has a beta of 1.96, meaning that its share price is 96% more volatile than the broader market.

Nuvectis Pharma has a net margin of 0.00% compared to Evotec's net margin of -26.20%. Evotec's return on equity of -24.93% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-161.00%	-98.88%
Evotec	-26.20%	-24.93%	-11.35%

In the previous week, Evotec had 3 more articles in the media than Nuvectis Pharma. MarketBeat recorded 3 mentions for Evotec and 0 mentions for Nuvectis Pharma. Evotec's average media sentiment score of 0.01 beat Nuvectis Pharma's score of 0.00 indicating that Evotec is being referred to more favorably in the news media.

Company	Overall Sentiment
Nuvectis Pharma	Neutral
Evotec	Neutral

Nuvectis Pharma has higher earnings, but lower revenue than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
Evotec	$891.97M	1.19	-$117.12M	N/A	N/A

96.8% of Nuvectis Pharma shares are owned by institutional investors. Comparatively, 5.8% of Evotec shares are owned by institutional investors. 30.5% of Nuvectis Pharma shares are owned by insiders. Comparatively, 1.0% of Evotec shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Nuvectis Pharma presently has a consensus price target of $10.00, indicating a potential downside of 8.59%. Evotec has a consensus price target of $7.00, indicating a potential upside of 134.11%. Given Evotec's stronger consensus rating and higher possible upside, analysts clearly believe Evotec is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Evotec	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Evotec beats Nuvectis Pharma on 9 of the 13 factors compared between the two stocks.

How does Nuvectis Pharma compare to Alvotech?

Nuvectis Pharma (NASDAQ:NVCT) and Alvotech (NASDAQ:ALVO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

Alvotech has higher revenue and earnings than Nuvectis Pharma. Alvotech is trading at a lower price-to-earnings ratio than Nuvectis Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
Alvotech	$588.90M	1.73	$27.92M	-$0.25	N/A

Nuvectis Pharma has a net margin of 0.00% compared to Alvotech's net margin of -14.36%. Alvotech's return on equity of -11.92% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-161.00%	-98.88%
Alvotech	-14.36%	-11.92%	-7.58%

Nuvectis Pharma has a beta of -0.11, indicating that its share price is 111% less volatile than the broader market. Comparatively, Alvotech has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market.

In the previous week, Alvotech had 2 more articles in the media than Nuvectis Pharma. MarketBeat recorded 2 mentions for Alvotech and 0 mentions for Nuvectis Pharma. Nuvectis Pharma's average media sentiment score of 0.00 equaled Alvotech'saverage media sentiment score.

Company	Overall Sentiment
Nuvectis Pharma	Neutral
Alvotech	Neutral

Nuvectis Pharma presently has a consensus price target of $10.00, suggesting a potential downside of 8.59%. Alvotech has a consensus price target of $7.60, suggesting a potential upside of 124.85%. Given Alvotech's higher probable upside, analysts clearly believe Alvotech is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

96.8% of Nuvectis Pharma shares are held by institutional investors. 30.5% of Nuvectis Pharma shares are held by insiders. Comparatively, 0.5% of Alvotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Alvotech beats Nuvectis Pharma on 9 of the 13 factors compared between the two stocks.

How does Nuvectis Pharma compare to Xeris Biopharma?

Xeris Biopharma (NASDAQ:XERS) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

In the previous week, Xeris Biopharma had 2 more articles in the media than Nuvectis Pharma. MarketBeat recorded 2 mentions for Xeris Biopharma and 0 mentions for Nuvectis Pharma. Xeris Biopharma's average media sentiment score of 0.85 beat Nuvectis Pharma's score of 0.00 indicating that Xeris Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Xeris Biopharma	Positive
Nuvectis Pharma	Neutral

Xeris Biopharma presently has a consensus target price of $10.80, suggesting a potential upside of 69.28%. Nuvectis Pharma has a consensus target price of $10.00, suggesting a potential downside of 8.59%. Given Xeris Biopharma's stronger consensus rating and higher possible upside, research analysts plainly believe Xeris Biopharma is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Xeris Biopharma has higher revenue and earnings than Nuvectis Pharma. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$291.85M	3.77	$550K	$0.06	106.33
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A

Xeris Biopharma has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.11, suggesting that its stock price is 111% less volatile than the broader market.

42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are held by institutional investors. 6.5% of Xeris Biopharma shares are held by insiders. Comparatively, 30.5% of Nuvectis Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Xeris Biopharma has a net margin of 3.81% compared to Nuvectis Pharma's net margin of 0.00%. Xeris Biopharma's return on equity of 735.00% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	3.81%	735.00%	3.24%
Nuvectis Pharma	N/A	-161.00%	-98.88%

Summary

Xeris Biopharma beats Nuvectis Pharma on 13 of the 15 factors compared between the two stocks.

Get Nuvectis Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVCT vs. The Competition

Export

Metric	Nuvectis Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$290.24M	$3.36B	$6.34B	$12.28B
Dividend Yield	N/A	2.32%	2.80%	5.36%
P/E Ratio	-8.35	19.02	20.92	25.48
Price / Sales	N/A	278.81	521.15	73.33
Price / Cash	N/A	125.35	43.18	55.00
Price / Book	20.26	6.90	9.98	7.01
Net Income	-$26.44M	$24.23M	$3.55B	$335.16M
7 Day Performance	-12.13%	0.65%	0.40%	-0.30%
1 Month Performance	27.51%	-0.55%	-0.04%	1.14%
1 Year Performance	8.86%	63.42%	34.95%	34.69%

Nuvectis Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
NVCT Nuvectis Pharma	0.3125 of 5 stars	$10.94 +2.9%	$10.00 -8.6%	-0.2%	$290.24M	N/A	N/A	8
COLL Collegium Pharmaceutical	2.7708 of 5 stars	$35.69 -0.3%	$57.50 +61.1%	+14.2%	$1.16B	$780.57M	17.50	210
DBVT DBV Technologies	2.3044 of 5 stars	$20.00 -1.8%	$40.25 +101.3%	+93.1%	$1.13B	$5.64M	N/A	80
EVO Evotec	2.9627 of 5 stars	$3.00 -2.0%	$7.00 +133.3%	-30.2%	$1.09B	$891.97M	N/A	4,553
ALVO Alvotech	2.9582 of 5 stars	$3.55 -1.1%	$7.60 +114.1%	-66.3%	$1.08B	$588.90M	N/A	1,460

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NVCT) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuvectis Pharma (NVCT) Competitors

NVCT vs. COLL, DBVT, EVO, ALVO, and XERS

How does Nuvectis Pharma compare to Collegium Pharmaceutical?

Summary

How does Nuvectis Pharma compare to DBV Technologies?

Summary

How does Nuvectis Pharma compare to Evotec?

Summary

How does Nuvectis Pharma compare to Alvotech?

Summary

How does Nuvectis Pharma compare to Xeris Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVCT vs. The Competition

Nuvectis Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuvectis Pharma (NVCT) Competitors

NVCT vs. COLL, DBVT, EVO, ALVO, and XERS

How does Nuvectis Pharma compare to Collegium Pharmaceutical?

Do analysts rate COLL or NVCT?

Is COLL or NVCT more profitable?

Which has better valuation & earnings, COLL or NVCT?

Which has more risk & volatility, COLL or NVCT?

Does the media prefer COLL or NVCT?

Do insiders & institutionals have more ownership in COLL or NVCT?

Summary

How does Nuvectis Pharma compare to DBV Technologies?

Do analysts rate DBVT or NVCT?

Which has higher valuation and earnings, DBVT or NVCT?

Which has more volatility and risk, DBVT or NVCT?

Is DBVT or NVCT more profitable?

Does the media refer more to DBVT or NVCT?

Do institutionals & insiders have more ownership in DBVT or NVCT?

Summary

How does Nuvectis Pharma compare to Evotec?

Which has more risk & volatility, NVCT or EVO?

Is NVCT or EVO more profitable?

Does the media favor NVCT or EVO?

Which has preferable earnings and valuation, NVCT or EVO?

Do insiders & institutionals have more ownership in NVCT or EVO?

Do analysts rate NVCT or EVO?

Summary

How does Nuvectis Pharma compare to Alvotech?

Which has higher earnings & valuation, NVCT or ALVO?

Is NVCT or ALVO more profitable?

Which has more volatility & risk, NVCT or ALVO?

Does the media prefer NVCT or ALVO?

Do analysts rate NVCT or ALVO?

Do institutionals and insiders have more ownership in NVCT or ALVO?

Summary

How does Nuvectis Pharma compare to Xeris Biopharma?

Does the media prefer XERS or NVCT?

Do analysts prefer XERS or NVCT?

Which has preferable earnings & valuation, XERS or NVCT?

Which has more risk and volatility, XERS or NVCT?

Do insiders & institutionals have more ownership in XERS or NVCT?

Is XERS or NVCT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVCT vs. The Competition

Nuvectis Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools